SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of earliest event reported: October 18, 2005
QLT INC.
---------------------
(Exact Name of Registrant as Specified in Charter)
<Table>
<Caption>
British Columbia, Canada 000-17082 N/A
------------------------ --------- -----------
(State or Other Jurisdiction of (Commission File Number) (I.R.S. Employer
Incorporation) Identification No.)
</Table>
887 Great Northern Way, Vancouver, B.C. Canada, V5T 4T5
-------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(604) 707-7000
-----------------------------------------
(Registrant's telephone number, including area code)
Not Applicable
-------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On October 18, 2005, QLT Inc. (the "Company") reported that its
alliance partner, Novartis, announced global Visudyne(R) (verteporfin) sales of
approximately US$124 million for the quarter ended September 30, 2005.
Since 1995 the Company has had a contractual collaboration, which we
often refer to as an alliance, with Novartis, for the worldwide joint
development and commercialization of photodynamic therapy products for eye
diseases, including Visudyne. Under the terms of our collaboration agreement,
the Company is responsible for manufacturing and product supply of Visudyne and
Novartis is responsible for marketing and distribution. The Company and Novartis
share equally the profits realized on revenues from product sales after
deductions for marketing costs and manufacturing costs (including any
third-party royalties).
The full text of the press release announcing such results is attached
hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference. Such information shall not be deemed "filed" for purposes
of Section 18 of the Securities and Exchange Act of 1934, as amended, and is not
incorporated by reference into any filing of the company, whether made before or
after the date hereof, regardless of any general incorporation language in such
filing.
ITEM 9.01 FINANCIAL STATEMENTS & EXHIBITS
C) EXHIBITS
Pursuant to the rules and regulations of the Securities and Exchange
Commission, the attached exhibit is deemed to have been furnished to, but not
filed with, the Securities and Exchange Commission:
Number Description
99.1 Press Release dated October 18, 2005 (Visudyne Sales for Q3 2005)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
QLT INC.
(Registrant)
By: /s/ Cameron Nelson
---------------------------
Cameron Nelson
Chief Financial Officer
Dated: October 18, 2005